- Home
- BZUN vs CKPT Comparison
BZUN vs CKPT Comparison
Compare BZUN & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZUN
- CKPT
- Stock Information
- Founded
- BZUN 2007
- CKPT 2014
- Country
- BZUN China
- CKPT United States
- Employees
- BZUN N/A
- CKPT N/A
- Industry
- BZUN Catalog/Specialty Distribution
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- BZUN Consumer Discretionary
- CKPT Health Care
- Exchange
- BZUN Nasdaq
- CKPT Nasdaq
- Market Cap
- BZUN 188.7M
- CKPT 172.4M
- IPO Year
- BZUN N/A
- CKPT 2017
- Fundamental
- Price
- BZUN $3.73
- CKPT $3.13
- Analyst Decision
- BZUN Buy
- CKPT Strong Buy
- Analyst Count
- BZUN 2
- CKPT 3
- Target Price
- BZUN $3.20
- CKPT $12.00
- AVG Volume (30 Days)
- BZUN 532.4K
- CKPT 753.4K
- Earning Date
- BZUN 03-20-2025
- CKPT 03-21-2025
- Dividend Yield
- BZUN N/A
- CKPT N/A
- EPS Growth
- BZUN N/A
- CKPT N/A
- EPS
- BZUN N/A
- CKPT N/A
- Revenue
- BZUN $1,312,737,613.00
- CKPT $47,000.00
- Revenue This Year
- BZUN $8.16
- CKPT N/A
- Revenue Next Year
- BZUN $4.71
- CKPT $300,658.78
- P/E Ratio
- BZUN N/A
- CKPT N/A
- Revenue Growth
- BZUN 7.26
- CKPT N/A
- 52 Week Low
- BZUN $2.11
- CKPT $1.38
- 52 Week High
- BZUN $4.38
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- BZUN 63.06
- CKPT 46.36
- Support Level
- BZUN $3.51
- CKPT $3.10
- Resistance Level
- BZUN $3.97
- CKPT $3.43
- Average True Range (ATR)
- BZUN 0.21
- CKPT 0.26
- MACD
- BZUN 0.02
- CKPT 0.00
- Stochastic Oscillator
- BZUN 73.91
- CKPT 33.03
About BZUN Baozun Inc.
Baozun Inc is an e-commerce service partner that helps brands execute their e-commerce strategies in China by selling their goods directly to customers online or by providing services to assist with their e-commerce operations. Its integrated end-to-end e-commerce service capabilities, omni-channel expertise, and technology-driven solutions. Company have two operating segments namely E-Commerce (including BEC and BZI) and Brand Management (BBM).
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.